Pfizer after the covid-19: new opportunity or substantial concentration risk

Abstract

The Equity Research report intends to introduce investors with key insights regarding the stock performance and intrinsic value of Pfizer. Covid-19 pandemic brought new opportunities, as well as new challenges and risks that need to be analyzed to provide a conclusion on which effect prevails and outweighs the other. The full spectrum, from industry analysis and trends to peer comparison represent a value-added approach to the company’s specific data. In the end, the valuation suggests a buy recommendation with Pfizer stock being priced at $56.08 per share by 31 December 2022, representing a 16% annualized shareholder return, including capital gains and dividend payment.